Abstract-Soluble vascular cell adhesion molecule-1 (sVCAM-1) is associated with hypertension, vascular inflammation, and systemic endothelial dysfunction. We evaluated whether elevated plasma sVCAM-1 is associated with impaired cerebrovascular function and mobility impairments in elderly people. We studied the cross-sectional relationships between plasma sVCAM-1 level, gait speed, and cerebrovascular hemodynamics, and its longitudinal relationship with falls in 680 community-dwelling participants aged ≥65 years in the Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly (MOBILIZE) Boston Study. Falls were recorded prospectively for 1 year on daily calendars. sVCAM-1 was measured by ELISA assay and beat-to-beat blood flow velocity in the middle cerebral artery during rest and in response to changes in end-tidal CO 2 was measured by transcranial Doppler ultrasound. sVCAM-1 concentration was 1094±340 ng/mL in normotensives, 1195±438 ng/mL in controlled hypertensives, and 1250±445 ng/mL in uncontrolled hypertensives (P=0.008). 
C erebrovascular diseases and mobility impairments are increasingly prevalent worldwide in older adults, conferring a major burden on health and healthcare costs. 1, 2 Recent studies suggest that these conditions may be linked through the development of cerebral endothelial dysfunction and associated cerebral microvascular disease. 3, 4 Cerebral endothelial dysfunction may be because of several conditions associated with aging, including hypertension and type-2 diabetes mellitus. 5, 6 It may also impair cerebral blood flow regulation and cerebral vasoreactivity, and ultimately lead to mobility impairments, including slowing of gait and falls. 7, 8 Soluble vascular cell adhesion molecule-1 (sVCAM-1) is a well-known biomarker of endothelium dysfunction that is associated with hypertension and atherosclerosis. 9, 10 It plays an important role in accelerating atherosclerosis by facilitating the attachment of inflammatory cells to the vascular endothelial wall and promoting their subsequent migration through the endothelium. 11, 12 The resulting inflammatory response, injury, and stiffening of the vascular wall may result in impaired cerebral blood flow regulation, especially endothelium-dependent vasodilatation in response to changes in blood end-tidal Pco 2 , and ischemic damage to the cerebral microvasculature. This microvascular disease often manifests as white matter hyperintensities in brain imaging studies.
We hypothesized that elevated plasma concentrations of sVCAM-1 associated with hypertension may be a marker of cerebral microvascular disease, characterized by reduced middle cerebral artery (MCA) blood flow, an impaired vascular responsiveness to CO 2 , slow gait speed, and increased risk of falls in elderly people. Therefore, we used transcranial Doppler (TCD) measures of cerebral blood flow regulation, plasma biomarkers, and mobility data from the Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly (MOBILIZE) Boston Study to explore the relationships between plasma levels of VCAM-1, cerebral blood flow dysregulation, and mobility impairment in a community-based population of older adults.
Methods

Participants
The study sample consisted of 680 individuals from the MOBILIZE Boston Study, which is a prospective cohort study of a unique set of risk factors for falls in community-dwelling seniors living in the Boston area. The design and methodology for this study have been previously described in detail. 13, 14 In brief, 680 patients eligible for this study were enrolled using door-to-door population-based recruitment. To be included, individuals had to be aged >70 years (or aged > 65 years if living with a participant), able to understand and communicate in English, able to walk 20 feet without personal assistance (walking aids permitted), expected to live in the area for at least 2 years, and provide written informed consent for blood withdrawal. Exclusion criteria included terminal disease, severe vision or hearing deficits, and Mini-Mental State Examination score <18. 15, 16 All subjects underwent a complete home and laboratory assessment of demographic characteristics, medical conditions, medications, functional status, gait speed, smoking status, alcohol use, blood pressure (BP), and cerebral hemodynamics, then they were followed up prospectively for falls using a monthly postcard calendar (see below). Only a subset of 419 subjects had an adequate temporal acoustic window to obtain reliable Doppler measures of cerebral blood flow velocity. Only those subjects with complete data for the variables of interest were included in the analyses.
Clinical Measures
Hypertension
Three BP categories were created: normotension, no history, or current evidence of hypertension; controlled hypertension, a history of hypertension, and antihypertensive treatment with normal BP (systolic BP <140 and diastolic BP <90 during the baseline clinical assessment); and uncontrolled hypertension, a history of hypertension with abnormal BP (systolic BP ≥140 or diastolic BP ≥90).
17,18
Gait Speed
Gait speed was assessed at the study center on a 4-m oval course. Gait speed was based on the fastest time of 2 trials of a usual-paced 4-m walk. The time to walk 4 m is a component of the Short Physical Performance Battery, which was used to assess gait speed. Gait speed was dichotomized into 2 groups, slow <0.80 m/s and fast ≥0.80 m/s, based on previously established threshold values for frailty, disability, and falls. 19, 20 
Falls Detection
During a 1-year follow-up period, a fall was defined as unintentionally coming to rest on the ground or other lower level not as a result of a major intrinsic event (eg, myocardial infarction, stroke, or seizure) or an overwhelming external hazard (eg, hit by a vehicle). 13, 21 Participants were instructed to complete and return monthly falls calendar postcards designed to be posted on a refrigerator. On the postcards, participants were to record an F for each fall on the day it occurred and an N on days when no falls occurred. This approach has been well validated for use in epidemiological cohort studies and described in previous studies. 22 All subjects who reported falls were also called to determine the circumstances of the fall and clinical outcomes, including whether any injuries (eg, fractures) or hospital visits occurred.
Biomarkers Measures
Concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sVCAM-1, and interleukin (IL)-6 were measured by ELISA assay (R&D Systems, Minneapolis, MN). For sICAM-1, this assay has a sensitivity of 0.35 ng/mL, and the day-to-day variability of the assay at concentrations of 64.2, 117, 290, and 453 ng/mL is 10.1%, 7.4%, 6.0%, and 6.1%, respectively. For sVCAM-1, the assay has a sensitivity of 2.0 ng/mL, and the day-to-day variability of the assay at concentrations of 9.8, 24.9, and 49.6 ng/mL is 10.2%, 8.5%, and 8.9%, respectively. For IL-6, the assay has a sensitivity of 0.094 pg/mL, and the day-to-day variability of the assay at concentrations of 0.49, 2.78, and 5.65 pg/mL is 9.6%, 7.2%, and 6.5%, respectively. In addition, the concentration of high sensitivity C-reactive protein was determined using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN), using reagents and calibrators from DiaSorin (Stillwater, MN). This high-sensitivity assay has a limit of detection of 0.03 mg/L. The day-to-day variability of the assay at concentrations of 0.91, 3.07, and 13.38 mg/L is 2.81%, 1.61%, and 1.1%, respectively. Nonfasting venous blood samples were collected from participants during the baseline clinical visit. Blood was collected in a 7.5-mL red-top tube, allowed to coagulate, and then centrifuged and decanted according to standard protocols. Serum samples were aliquoted into Nunc (Nalgene NUNC; Thermo Fisher Scientific Inc, Waltham, MA) cryotubes, labeled, and stored in −80°C freezers. All assays were performed by Dr Nader Rifai's group at Boston Children's Hospital.
TCD Ultrasound Measures
Subjects reported to the Cerebrovascular Laboratory at the Hebrew SeniorLife Institute for Aging Research and were instrumented for heart rate (ECG) and beat-to-beat arterial pressure monitoring (Finapres; Ohmeda Monitoring Systems, Englewood, CO). 23 End-tidal CO 2 was measured using a Vacumed CO 2 Analyzer (Ventura, CA) attached to a nasal cannula. TCD ultrasonography (MultiDop X4, DWL-Transcranial Doppler Systems Inc, Sterling, VA) was used to measure MCA mean blood flow velocity (BFV) at rest and in response to changes in end-tidal CO 2 , as previously described. 24 The MCA signal was identified according to standard criteria 25 and recorded at a depth of 50 to 60 mm. The envelope of the velocity waveform, derived from a fast-Fourier analysis of the Doppler frequency signal, was digitized at 500 Hz, displayed simultaneously with the arterial pressure monitoring, ECG, and end-tidal CO 2 signals, and stored for later off-line analysis. Previous studies, using a variety of techniques (133Xe, SPECT, magnetic resonance imaging) and stimuli, have validated TCD measures of relative changes in cerebral flow velocity as representative of changes in cerebral blood flow. 26, 27 CO 2 Vasoreactivity Protocol BFV in the MCA was measured continuously while subjects inspired a gas mixture of 8% CO 2 , 21% O 2 , and balance nitrogen for 2 minutes and then mildly hyperventilated to an end-tidal CO 2 of ≈25 mm Hg for 2 minutes. Percentage change in MCA BFV from baseline was plotted against end-tidal CO 2 while breathing room air, 8% CO 2 , or hyperventilating. Cerebral vasoreactivity was measured as the slope of this relationship and expressed as percentage change in BFV per mm Hg change in end-tidal CO 2 . Cerebral vasomotor range (VMR) was calculated as the difference between the highest BFV during CO 2 inhalation (hypercapnia) and the lowest BFV during hyperventilation (hypocapnia) divided by the change in end-tidal CO 2 during the 6 minutes of the vasoreactivity protocol.
Other Covariates
Covariates included sociodemographic characteristics, physiological risk factors, health status, and amount of physical activity. Sociodemographic characteristics assessed in the home interview included age, sex, race (self-identified), and years of education. We used the validated Physical Activity Scale for the Elderly to measure physical activity in the previous week. 28 Participants were asked about physician-diagnosed major medical conditions. Details of the study methods were published previously. 13, 14 Orthostatic hypotension was defined as a drop in systolic BP of ≥20 mm Hg or a drop in diastolic BP of ≥10 mm Hg within 3 minutes of standing.
Diabetes mellitus was defined using an algorithm based on self-reported diabetes mellitus, use of antidiabetic medications, and laboratory measures from the baseline clinic visit including random glucose (>200 mg/dL) and hemoglobin A 1c (>7%). Body mass index (calculated as weight in kilograms divided by height in meters squared) was by guest on April 18, 2017 http://hyper.ahajournals.org/ Downloaded from calculated from measured height and weight. Cognitive status was defined as "cognitive impairment" (Mini-Mental State Examination <24) and "no cognitive impairment" (Mini-Mental State Examination ≥24). Comorbidity index was the number of comorbidities or medical conditions. Medication use (antihypertensive, antidepressant, and benzodiazepine) was also assessed.
Medication Use
The use of cardiovascular medications was assessed at baseline during an in-person interview by asking the participant to report all medications that were taken for at least a 2-week period. Dose information was recorded from medication bottles. Drug data were coded according to the Iowa Drug Information System and classified into the following 6 categories: α blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β blockers, diuretics, and calcium channel blockers. In addition, we grouped participants into those taking any cardiovascular medications and those on angiotensin system-blocking medications (angiotensin-converting enzyme and angiotensin receptor blockers). Psychotropic medications, such as antidepressants and benzodiazepines, were also assessed also assessed.
Ethics Statement
The MOBILIZE Boston Study was reviewed and approved by the Hebrew SeniorLife Institutional Review Board. Written informed consent was obtained from each participant. The study was conducted according to the principles of the Helsinki Declaration.
Data Analysis
Concentrations of sVCAM-1 and sICAM-1 were log-transformed to approximate a normal distribution before modeling as continuous variables. We also divided the distributions of sVCAM-1 into quintiles according to the distribution in the entire study population for categorical analyses. Participants were grouped into those with normotension, controlled hypertension, and uncontrolled hypertension; slow (<0.8 m/s) and fast (>0.8 m/s) gait speed or fall categories (none versus >1 fall per year of follow-up or no falls, noninjurious, and injurious falls). We compared baseline characteristics of different groups of study participants by using t tests, χ 2 tests, or Wilcoxon rank-sum tests. We used multivariate linear regression to examine the cross-sectional relationships between log-transformed sVCAM-1 levels and continuous outcomes (eg, gait speed and CVMR) and logistic regression to estimate the relative risk and 95% confidence intervals for quintiles of sVCAM and binary outcomes (eg, hypertensive, gait speed, or falls groups). In these analyses, we had at least 85% power to detect a significant linear trend (2-sided P<0.05) across quintiles in which the risk in the highest quintile relative to the lowest was at least 1.5. 29 Analyses were adjusted for the following groups of confounders: (1) other biomarkers (ICAM-1, IL-6, and C-reactive protein); (2) sociodemographic conditions (age, sex, white race, education level, body mass index, current smoker, alcohol use); (3) health conditions (diabetes mellitus, Hypertension, congestive heart failure, hyperlipidemia, cognitive status, depression, any cardiovascular medications, coronary artery disease, and previous stroke); and (4) physical activity level.
Subjects with missing data for the main outcomes, including sVCAM-1, hypertension, gait, falls, and BFV were excluded. All analyses were performed using SAS software, version 9.3 (SAS Institute Inc, Cary, NC). A 2-sided P value of <0.05 was considered indicative of statistical significance. Table 1 summarizes the demographic and clinical characteristics of the MOBILIZE Boston Study participants with sVCAM-1 and sICAM-1 measurements. The mean age was 78±5 years and 62% were women. Three hundred and sixtyone (54%) participants had controlled hypertension, and 162 (24%) had uncontrolled hypertension. TCD measures with cerebral CO 2 VMR data were available in 419 (62%) participants. Data for the 419 subjects seemed representative of the larger population, and there was no significant difference in demographics or the number of falls between those with and without a TCD window. sVCAM-1 concentration increased with age (P<0.0001) and was higher in men than in women (P=0.0007). The geometric mean of IL-6 and hs-CRP at baseline was, respectively, 2.58±0.08 and 1.62±0.07. sVCAM-1 was correlated with IL-6 (r=0.21; P<0.0001) but not with hs-CRP (r=0.07; P=0.08). 
Results
Participants
sVCAM-1 and Gait Speed
In a cross-sectional linear regression analysis, VCAM-1 plasma concentration was negatively associated with gait speed (r=−0.21; P<0.0001). When gait speed was dichotomized into slow (<0.8 m/s) and fast (>0.8 m/s) groups, an adjusted logistic regression analysis also showed a significant relationship with sVCAM-1 concentration (OR, 1. 
sVCAM-1 and Falls >1 Year
During 1 year of follow-up, 258 subjects fell with an annual incidence of 38.4%. Subjects who developed falls had significantly elevated levels of sVCAM-1 (OR, 1.04 [1.02-1.09]; P=0.0182). Compared with the lowest quintile, the third, fourth, and fifth quintiles of sVCAM-1 were also significantly associated with ≥1 falls over 1 year (Table 3) . We also stratified the subjects into 3 groups of fallers and examined sVCAM-1 levels in each group. sVCAM-1 concentration was 1156.9±421.3 in nonfallers, 1215.4±436.6 in noninjurious fallers, and 1277.1±452.9 in injurious fallers (P=0.0019). The third, fourth, and fifth quintiles of sVCAM-1 were also significantly associated with injurious falls over 1 year compared with the lowest quintile (Table S3 ). There was no interaction between sVCAM-1 and hypertension on falls status.
sVCAM-1 and Cerebral Blood Flow Regulation (n=419)
To determine whether cerebral endothelial dysfunction might explain the association between sVCAM-1, gait speed, and risk of falls, we examined the relationship between sVCAM-1, BFV, and cerebral VMR in response to CO 2 .
sVCAM-1 was negatively correlated with resting cerebral BFV (r=−0.12; P=0.017). sVCAM-1 was also negatively associated with cerebral VMR (P=0.040; Figure) . After adjustment for relevant covariates, the multivariate linear regression analysis showed that a 10% increase in sVCAM-1 was associated with a lower VMR by 2.40% (P=0.0048; Table S4 ).
Soluble ICAM-1
There were no significant relationships between any of the study outcomes and circulating levels of sICAM-1.
Discussion
Our study results show that elevated plasma levels of sVCAM-1 are associated with (1) slower gait speed in older adults with hypertension, (2) incident falls, and (3) injurious falls. The association of sVCAM-1 with cerebral blood flow dysregulation suggests that sVCAM-1 may be involved in the pathogenesis of cerebral microvascular disease and its clinical consequences, namely slowing of gait and falls, in older people.
The cell adhesion molecule-regulated process of leukocyte recruitment often results in endothelial cell dysfunction, which can be manifested as impaired endothelium-dependent vasorelaxation in arterioles, excess fluid filtration in capillaries, or enhanced protein extravasation in venules. 11 Consequently, sVCAM-1 has been implicated in a variety of vascular disorders (eg, ischemia/reperfusion, atherosclerosis, allograft dysfunction, and vasculitis) and an enhanced expression of sVCAM-1 has been invoked to explain the exaggerated microvascular dysfunction associated with cardiovascular risk factors (hypertension, hypercholesterolemia, and diabetes mellitus). Cerebral microvascular disease has been reported to be associated with slow gait, executive dysfunction, and depressive symptoms. 8 This association may be because of ischemic injury to areas of the brain that control motor function and attentional processes. Because sVCAM-1 is known to be associated with ischemic injury and endothelial dysfunction in other areas of the circulation, its relationship to abnormal cerebral vasoreactivity in response to CO 2 is biologically plausible. Our observations are supported by those of Novak et al, 31 who found an association between sVCAM-1 and CO 2 vasoreactivity, as well as gray matter atrophy, in diabetic subjects and older controls. Small differences in cerebral vasoreactivity or cerebral blood flow are associated with rather large effects on white matter hyperintensities. 32 Therefore, sVCAM-1 may serve as a clinical biomarker of cerebrovascular disease and its clinical consequences. Furthermore, elevated levels of plasma sVCAM-1 (>1200 ng/mL) may signal a significant risk of hypertension on the cerebral circulation and its potential adverse effects on mobility. There is no correlation with sICAM-1. This suggests that sVCAM-1 has the predominant effect on the cerebrovascular endothelium.
Our study had some limitations. First, the cross-sectional design precludes investigating the temporal relation between sVCAM-1 elevation and hypertension, cerebral blood flow dysregulation, and slowing of gait speed. However, we were able to use longitudinal fall follow-up data to demonstrate a relationship between sVCAM-1 and falls incidence over 1 year. The second limitation is the smaller number of subjects with adequate TCD data because of an inadequate temporal bone window to obtain reliable Doppler measures of cerebral BFV. This is a common problem among elderly people, affecting approximately one third of elderly subjects in previous studies. 33 Therefore, our findings may not be representative of all older adults. The third limitation is that we have examined only an endothelial dysfunction marker, and sVCAM-1 may act through other pathways to impair mobility. Inflammatory markers were associated with poor physical performance and muscle strength in older patients. 34 For example, by inducing T-cell chemotaxis and inflammatory responses, synovial inflammation in hips or knees may affect gait. 35 We tried to address this by controlling for the inflammatory biomarkers CRP and IL-6 in the multivariable analysis. Endothelial nitric oxide synthase (eNOS) regulates vascular tone through the production of NO. NO-dependent dilation is also impaired by oxidative stress that is elevated in hypertensive arteries. 36 There may be a host of other factors that could be responsible for abnormal vasoreactivity and impaired gait speed. Finally, in this study we only measured serum soluble vascular adhesion molecules as indirect measures of endothelial damage although vasoreactivity is a direct measure of endothelial function in the cerebral vessels. 33 Our study has several strengths: first, we used both a crosssectional and longitudinal study design in which we assessed incident cases of falls that occurred after the measurement of biomarkers. The adhesion molecule (VCAM and ICAM) concentrations were comparable with those in previous studies. 37 We included functional (TCD) measures of the cerebral circulation. We believe our work is novel in identifying a potential biomarker of falls risk, and suggests a potential vascular mechanism of mobility impairment in older people associated with ischemic damage to the microvasculature of the brain. Previous studies showed that persistent hypertension was associated with both a slower walking speed and greater decline in walking speed in the elderly. 38 The prevalence of hypertension was ≈80%, which is similar to that observed in other populations. 8, 39 Since our study participants were derived from a random population of elderly people over the age of 70 years from a defined geographic area of Massachusetts, we believe our subjects are representative of this region.
Finally, our findings may have practical implications for clinicians who in the future may be able to use sVCAM-1 measurements to determine brain endothelial and parenchyma health without the use of expensive imaging studies and intervene early to prevent the clinical consequences of cerebral microvascular disease in elderly people.
Perspectives
Elevated plasma levels of sVCAM-1 may be a marker of chronic cerebral blood flow dysregulation caused by cerebral endothelial damage from hypertension. It may also signal the clinical consequences of cerebral microvascular disease, including slow gait speed and injurious falls among elderly people. Each of these finding suggests that sVCAM-1 may provide an attractive way to detect cerebral endothelium damage and guide future therapeutic interventions. Additional prospective studies are needed to confirm our findings and determine the sequence of events in the pathogenesis of cerebral microvascular disease and its clinical manifestations. 
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